A Multicenter, Single-Arm, Open-Label, Expanded Access Program for Lenalidomide With or Without Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Trial Information

A Multicenter, Single-Arm, Open-Label, Expanded Access Program for Lenalidomide With or Without Dexamethasone in Previously Treated Subjects With Multiple Myeloma

This was a multicenter, non-randomized, open-label, uncontrolled, single-arm treatment study
of lenalidomide as monotherapy or in combination with dexamethasone in subjects with
previously treated relapsed or refractory multiple myeloma, with measurable myeloma
paraprotein in serum and/or urine. Subjects who met all of the eligibility criteria were
enrolled into the study. Screening procedures took place within 28 days of first dose.
Subjects who qualified for participation received oral lenalidomide at a dose of 25 mg daily
for 21 days every 28 days.

Subjects had the following options for dexamethasone treatment at the discretion of the
treating physician:

Option A: No dexamethasone.

Option B: Oral pulse dexamethasone administered at a dose of 40 mg daily on Days 1-4, 9-12,
and 17-20 for each 28-day cycle.

Option C: Oral pulse dexamethasone administered at a dose of 20 mg daily on Days 1-4, 9-12,
and 17-20 for each 28-day cycle.

Option D: Oral dexamethasone administered at a dose of 40 mg weekly on Days 1, 8, 15, and 22
for each 28-day cycle for all cycles. Treatment was to be continued as tolerated until
disease progression developed.

Doses of lenalidomide were allowed to be reduced first from 25 mg to 15 mg and then in 5-mg
decrements due to lenalidomide toxicity. Subjects who could not tolerate a daily dose of 5
mg for 21 days every 28 days were discontinued from treatment. At the discretion of the
investigator, doses of dexamethasone were modified due to dexamethasone toxicity. Dose
reduction and discontinuation schemes for dexamethasone varied according to the treatment
option administered.

Study visits occurred every 2 weeks for the first 3 cycles of therapy and then every 4 weeks
after the third cycle until disease progression was documented, study drug was discontinued
for another reason, or lenalidomide became commercially available for this indication.

Inclusion Criteria:

1. Must understand and voluntarily sign an informed consent form.

2. Must be > or = to 18 years of age at the time of signing the informed consent form.

3. Must be able to adhere to the study visit schedule and other protocol requirements.

4. Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles
of anti-myeloma treatment or that has relapsed with progressive disease after
treatment.

5. Subjects may have been previously treated with thalidomide and/or radiation therapy.
In addition, radiation therapy initiated prior to or at baseline (Day 1) may be given
concurrently with study therapy, provided that all other eligibility criteria are
satisfied.

8. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
test within 7 days of starting study drug. In addition, sexually active WCBP must
agree to use adequate contraceptive methods (oral, injectable, or implantable
hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive
with spermicide; or vasectomized partner) while on study medication.

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

2. Pregnant or lactating females.

3. Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study.

5. Prior history of malignancies other than multiple myeloma (except for basal cell or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast)
unless the subject has been free of the disease for >/= 1 year.

6. Known hypersensitivity to thalidomide or dexamethasone.

7. Prior history of uncontrollable side effects to dexamethasone therapy.

8. The development of a desquamating rash while taking thalidomide.

9. Use of any standard/experimental anti-myeloma drug therapy within 28 days of the
initiation of study drug treatment or use of any experimental non-drug therapy (e.g.,
donor leukocyte/mononuclear cell infusions) within 56 days of the initiation of study
drug treatment.

Outcome Measure:

Outcome Description:

Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study.

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.